Anticancer Drug Resistance: Advances in Molecular and Clinical Research
Over the last 50 years, drug development and clinical trials have resulted in successful complete responses in diseases such as childhood leukemia, testicular cancer and Hodgkin's disease. We are still, however, confronted with over 500,000 cancer-related deaths per year. Clearly, the phenomeno...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Boston, MA
Springer US
1994
|
| Schriftenreihe: | Cancer Treatment and Research
73 |
| Schlagworte: | |
| Online-Zugang: | DE-355 URL des Erstveröffentlichers |
| Zusammenfassung: | Over the last 50 years, drug development and clinical trials have resulted in successful complete responses in diseases such as childhood leukemia, testicular cancer and Hodgkin's disease. We are still, however, confronted with over 500,000 cancer-related deaths per year. Clearly, the phenomenon of drug resistance is largely responsible for these failures and continues to be an area of active investigation. Since the last volume in this series, we have learned that the energy-dependent drug efflux protein, p-glycoprotein, encoded by the MDR 1 gene, is a member of a family of structurally related transport polypeptides, thus allowing us to explore the relationship between structure and function. In addition to ongoing well designed clinical trials aimed at reversing MDR mediated drug resistance, the first gene therapy studies with the MDR 1 gene retrovirally transduced into human bone marrow cells are about to be initiated. Although MDR is currently the most understood mechanism of drug resistance, we are uncovering increasing knowledge of alternative molecular and biochemical mechanisms of drug resistance to antimetabolites, cisplatin and alkylating agents and developing new strategies for circumventing such resistance. It is clear that drug resistance is complex, and many mechanisms exist by which cancer cells may overcome the cytotoxicity of our known chemotherapeutic agents. As our understanding of each of these mechanisms expands, well designed models will be necessary to test laboratory hypotheses and determine their relationship to drug resistance in humans. It is this integration of basic science and clinical investigation that will both advance our scientific knowledge and result in the improvement of cancer therapy |
| Beschreibung: | 1 Online-Ressource (XIII, 294 p) |
| ISBN: | 9781461526322 |
| DOI: | 10.1007/978-1-4615-2632-2 |
Internformat
MARC
| LEADER | 00000nam a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV046144769 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1994 xx o|||| 00||| eng d | ||
| 020 | |a 9781461526322 |9 978-1-4615-2632-2 | ||
| 024 | 7 | |a 10.1007/978-1-4615-2632-2 |2 doi | |
| 035 | |a (ZDB-2-SME)978-1-4615-2632-2 | ||
| 035 | |a (OCoLC)1119089669 | ||
| 035 | |a (DE-599)BVBBV046144769 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.994 |2 23 | |
| 084 | |a XI 7000 |0 (DE-625)153024:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Anticancer Drug Resistance |b Advances in Molecular and Clinical Research |c edited by Lori J. Goldstein, Robert F. Ozols |
| 264 | 1 | |a Boston, MA |b Springer US |c 1994 | |
| 300 | |a 1 Online-Ressource (XIII, 294 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Cancer Treatment and Research |v 73 | |
| 520 | |a Over the last 50 years, drug development and clinical trials have resulted in successful complete responses in diseases such as childhood leukemia, testicular cancer and Hodgkin's disease. We are still, however, confronted with over 500,000 cancer-related deaths per year. Clearly, the phenomenon of drug resistance is largely responsible for these failures and continues to be an area of active investigation. Since the last volume in this series, we have learned that the energy-dependent drug efflux protein, p-glycoprotein, encoded by the MDR 1 gene, is a member of a family of structurally related transport polypeptides, thus allowing us to explore the relationship between structure and function. In addition to ongoing well designed clinical trials aimed at reversing MDR mediated drug resistance, the first gene therapy studies with the MDR 1 gene retrovirally transduced into human bone marrow cells are about to be initiated. Although MDR is currently the most understood mechanism of drug resistance, we are uncovering increasing knowledge of alternative molecular and biochemical mechanisms of drug resistance to antimetabolites, cisplatin and alkylating agents and developing new strategies for circumventing such resistance. It is clear that drug resistance is complex, and many mechanisms exist by which cancer cells may overcome the cytotoxicity of our known chemotherapeutic agents. As our understanding of each of these mechanisms expands, well designed models will be necessary to test laboratory hypotheses and determine their relationship to drug resistance in humans. It is this integration of basic science and clinical investigation that will both advance our scientific knowledge and result in the improvement of cancer therapy | ||
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Cancer Research | |
| 650 | 4 | |a Pharmacology/Toxicology | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Toxicology | |
| 650 | 0 | 7 | |a Cytostatikum |0 (DE-588)4068347-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Resistenz |0 (DE-588)4136408-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelresistenz |0 (DE-588)4143180-7 |2 gnd |9 rswk-swf |
| 655 | 7 | |8 1\p |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 0 | 2 | |a Arzneimittelresistenz |0 (DE-588)4143180-7 |D s |
| 689 | 0 | |8 2\p |5 DE-604 | |
| 689 | 1 | 0 | |a Resistenz |0 (DE-588)4136408-9 |D s |
| 689 | 1 | 1 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 1 | |8 3\p |5 DE-604 | |
| 700 | 1 | |a Goldstein, Lori J. |4 edt | |
| 700 | 1 | |a Ozols, Robert F. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780792328360 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461361299 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461526339 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4615-2632-2 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 3\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-031524954 | |
| 966 | e | |u https://doi.org/10.1007/978-1-4615-2632-2 |l DE-355 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1823607507868712960 |
|---|---|
| adam_text | |
| any_adam_object | |
| author2 | Goldstein, Lori J. Ozols, Robert F. |
| author2_role | edt edt |
| author2_variant | l j g lj ljg r f o rf rfo |
| author_facet | Goldstein, Lori J. Ozols, Robert F. |
| building | Verbundindex |
| bvnumber | BV046144769 |
| classification_rvk | XI 7000 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-1-4615-2632-2 (OCoLC)1119089669 (DE-599)BVBBV046144769 |
| dewey-full | 616.994 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994 |
| dewey-search | 616.994 |
| dewey-sort | 3616.994 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-1-4615-2632-2 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000zcb4500</leader><controlfield tag="001">BV046144769</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1994 xx o|||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781461526322</subfield><subfield code="9">978-1-4615-2632-2</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-4615-2632-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-1-4615-2632-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119089669</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046144769</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 7000</subfield><subfield code="0">(DE-625)153024:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Anticancer Drug Resistance</subfield><subfield code="b">Advances in Molecular and Clinical Research</subfield><subfield code="c">edited by Lori J. Goldstein, Robert F. Ozols</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Boston, MA</subfield><subfield code="b">Springer US</subfield><subfield code="c">1994</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XIII, 294 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Cancer Treatment and Research</subfield><subfield code="v">73</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Over the last 50 years, drug development and clinical trials have resulted in successful complete responses in diseases such as childhood leukemia, testicular cancer and Hodgkin's disease. We are still, however, confronted with over 500,000 cancer-related deaths per year. Clearly, the phenomenon of drug resistance is largely responsible for these failures and continues to be an area of active investigation. Since the last volume in this series, we have learned that the energy-dependent drug efflux protein, p-glycoprotein, encoded by the MDR 1 gene, is a member of a family of structurally related transport polypeptides, thus allowing us to explore the relationship between structure and function. In addition to ongoing well designed clinical trials aimed at reversing MDR mediated drug resistance, the first gene therapy studies with the MDR 1 gene retrovirally transduced into human bone marrow cells are about to be initiated. Although MDR is currently the most understood mechanism of drug resistance, we are uncovering increasing knowledge of alternative molecular and biochemical mechanisms of drug resistance to antimetabolites, cisplatin and alkylating agents and developing new strategies for circumventing such resistance. It is clear that drug resistance is complex, and many mechanisms exist by which cancer cells may overcome the cytotoxicity of our known chemotherapeutic agents. As our understanding of each of these mechanisms expands, well designed models will be necessary to test laboratory hypotheses and determine their relationship to drug resistance in humans. It is this integration of basic science and clinical investigation that will both advance our scientific knowledge and result in the improvement of cancer therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer Research</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology/Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Resistenz</subfield><subfield code="0">(DE-588)4136408-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelresistenz</subfield><subfield code="0">(DE-588)4143180-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="8">1\p</subfield><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Arzneimittelresistenz</subfield><subfield code="0">(DE-588)4143180-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Resistenz</subfield><subfield code="0">(DE-588)4136408-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="8">3\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goldstein, Lori J.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ozols, Robert F.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780792328360</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461361299</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461526339</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-4615-2632-2</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">3\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031524954</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4615-2632-2</subfield><subfield code="l">DE-355</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046144769 |
| illustrated | Not Illustrated |
| indexdate | 2025-02-09T19:00:43Z |
| institution | BVB |
| isbn | 9781461526322 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031524954 |
| oclc_num | 1119089669 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XIII, 294 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1994 |
| publishDateSearch | 1994 |
| publishDateSort | 1994 |
| publisher | Springer US |
| record_format | marc |
| series2 | Cancer Treatment and Research |
| spelling | Anticancer Drug Resistance Advances in Molecular and Clinical Research edited by Lori J. Goldstein, Robert F. Ozols Boston, MA Springer US 1994 1 Online-Ressource (XIII, 294 p) txt rdacontent c rdamedia cr rdacarrier Cancer Treatment and Research 73 Over the last 50 years, drug development and clinical trials have resulted in successful complete responses in diseases such as childhood leukemia, testicular cancer and Hodgkin's disease. We are still, however, confronted with over 500,000 cancer-related deaths per year. Clearly, the phenomenon of drug resistance is largely responsible for these failures and continues to be an area of active investigation. Since the last volume in this series, we have learned that the energy-dependent drug efflux protein, p-glycoprotein, encoded by the MDR 1 gene, is a member of a family of structurally related transport polypeptides, thus allowing us to explore the relationship between structure and function. In addition to ongoing well designed clinical trials aimed at reversing MDR mediated drug resistance, the first gene therapy studies with the MDR 1 gene retrovirally transduced into human bone marrow cells are about to be initiated. Although MDR is currently the most understood mechanism of drug resistance, we are uncovering increasing knowledge of alternative molecular and biochemical mechanisms of drug resistance to antimetabolites, cisplatin and alkylating agents and developing new strategies for circumventing such resistance. It is clear that drug resistance is complex, and many mechanisms exist by which cancer cells may overcome the cytotoxicity of our known chemotherapeutic agents. As our understanding of each of these mechanisms expands, well designed models will be necessary to test laboratory hypotheses and determine their relationship to drug resistance in humans. It is this integration of basic science and clinical investigation that will both advance our scientific knowledge and result in the improvement of cancer therapy Oncology Cancer Research Pharmacology/Toxicology Oncology Toxicology Cytostatikum (DE-588)4068347-3 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Resistenz (DE-588)4136408-9 gnd rswk-swf Arzneimittelresistenz (DE-588)4143180-7 gnd rswk-swf 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content Krebs Medizin (DE-588)4073781-0 s Cytostatikum (DE-588)4068347-3 s Arzneimittelresistenz (DE-588)4143180-7 s 2\p DE-604 Resistenz (DE-588)4136408-9 s 3\p DE-604 Goldstein, Lori J. edt Ozols, Robert F. edt Erscheint auch als Druck-Ausgabe 9780792328360 Erscheint auch als Druck-Ausgabe 9781461361299 Erscheint auch als Druck-Ausgabe 9781461526339 https://doi.org/10.1007/978-1-4615-2632-2 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 3\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Anticancer Drug Resistance Advances in Molecular and Clinical Research Oncology Cancer Research Pharmacology/Toxicology Oncology Toxicology Cytostatikum (DE-588)4068347-3 gnd Krebs Medizin (DE-588)4073781-0 gnd Resistenz (DE-588)4136408-9 gnd Arzneimittelresistenz (DE-588)4143180-7 gnd |
| subject_GND | (DE-588)4068347-3 (DE-588)4073781-0 (DE-588)4136408-9 (DE-588)4143180-7 (DE-588)4143413-4 |
| title | Anticancer Drug Resistance Advances in Molecular and Clinical Research |
| title_auth | Anticancer Drug Resistance Advances in Molecular and Clinical Research |
| title_exact_search | Anticancer Drug Resistance Advances in Molecular and Clinical Research |
| title_full | Anticancer Drug Resistance Advances in Molecular and Clinical Research edited by Lori J. Goldstein, Robert F. Ozols |
| title_fullStr | Anticancer Drug Resistance Advances in Molecular and Clinical Research edited by Lori J. Goldstein, Robert F. Ozols |
| title_full_unstemmed | Anticancer Drug Resistance Advances in Molecular and Clinical Research edited by Lori J. Goldstein, Robert F. Ozols |
| title_short | Anticancer Drug Resistance |
| title_sort | anticancer drug resistance advances in molecular and clinical research |
| title_sub | Advances in Molecular and Clinical Research |
| topic | Oncology Cancer Research Pharmacology/Toxicology Oncology Toxicology Cytostatikum (DE-588)4068347-3 gnd Krebs Medizin (DE-588)4073781-0 gnd Resistenz (DE-588)4136408-9 gnd Arzneimittelresistenz (DE-588)4143180-7 gnd |
| topic_facet | Oncology Cancer Research Pharmacology/Toxicology Oncology Toxicology Cytostatikum Krebs Medizin Resistenz Arzneimittelresistenz Aufsatzsammlung |
| url | https://doi.org/10.1007/978-1-4615-2632-2 |
| work_keys_str_mv | AT goldsteinlorij anticancerdrugresistanceadvancesinmolecularandclinicalresearch AT ozolsrobertf anticancerdrugresistanceadvancesinmolecularandclinicalresearch |